Biogen (BIIB) Tops Q2 EPS by 56c, FY Guidance Tops Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB), Eisai Highlight Detailed Results from Phase II Clinical Study of Elenbecestat at AAIC 2018
July 25, 2018 10:38 AM EDTEisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced detailed results from a Phase II clinical study (Study 202) of the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) at the Alzheimers Association International Conference (AAIC) 2018 being held in Chicago, Illinois, United States, from July 22 to 26, 2018. This poster presentation was accepted as a Late Breaking Abstract for AAIC (Poster No.: P4-389).
Study 202 (ClinicalTrials.gov identifier NCT02322021) is a multicenter, randomized, double-blind, placebo-controlled parallel-group 18-month Phase II clinical study, conducted in the United States in patients with... More
Biogen (BIIB) PT Raised to $357 at RBC Capital
July 25, 2018 7:44 AM EDTRBC Capital raised its price target on Biogen (NASDAQ: BIIB) to $357.00 (from $349.00) while maintaining a Sector Perform rating.
Analyst Brian Abraham said the solid quarter with guidance raise should help keep enthusiasm high for BIIB following recent de-risking of key Alzheimer's portfolio.
... MoreBiogen (BIIB) PT Raised to $348 at Baird
July 25, 2018 6:40 AM EDTBaird raised its price target on Biogen (NASDAQ: BIIB) to $348.00 (from $323.00) while maintaining a Neutral rating.
Analyst Brian Skorney commented, "Biogen reported in-line revenues of $3.4B and EPS of $5.80, beating consensus at $5.21. A return for growth for Spinraza and solid performance... More
Biogen (BIIB) PT Raised to $320 at Barclays
July 25, 2018 3:35 AM EDTBarclays raised its price target on Biogen (NASDAQ: BIIB) to $320.00 (from $295.00) while maintaining a Equalweight rating.
Analyst Geoff Meacham believes good Q2 results from Tuesday should provide downside support for the equity in Wednesday's trading session should the BAN2401 presentation not meet what... More
Biogen (BIIB) Acquires Muscle Enhancement Program from AliveGen
July 24, 2018 6:42 AM EDTIn addition to earnings, Biogen (NASDAQ: BIIB) announced it has acquired ALG-801 (Phase 1a) and ALG-802 (preclinical) from AliveGen, Inc. ALG-801 (now known as BIIB110) and ALG-802 represent novel ways of targeting the myostatin pathway, which is one of the most thoroughly studied approaches... More
